$NAVB Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in NAVIDEA BIOPHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in NAVIDEA BIOPHARMACEUTICALS, INC.. Get notifications about new insider transactions in NAVIDEA BIOPHARMACEUTICALS, INC. for free.
Page: < prev 1 2 3 4 5 5 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Nov 17 2014 | NAVB | NAVIDEA BIOPHARMAC ... | GOLDBERG MICHAEL M | Director | Buy | P | 1.06 | 71,641 | 75,853 | 261,352 | 189.7 K to 261.4 K (+37.76 %) |
Nov 12 2014 | NAVB | NAVIDEA BIOPHARMAC ... | DRAKE PETER F | Director | Grant | A | 1.32 | 10,973 | 14,484 | 70,223 | 59.3 K to 70.2 K (+18.52 %) |
Nov 12 2014 | NAVB | NAVIDEA BIOPHARMAC ... | FORD BRENDAN A | Director | Buy | P | 1.03 | 10,000 | 10,300 | 180,696 | 170.7 K to 180.7 K (+5.86 %) |
Nov 12 2014 | NAVB | NAVIDEA BIOPHARMAC ... | FORD BRENDAN A | Director | Grant | A | 1.32 | 11,446 | 15,109 | 170,696 | 159.3 K to 170.7 K (+7.19 %) |
Nov 12 2014 | NAVB | NAVIDEA BIOPHARMAC ... | GOLDBERG MICHAEL M | Director | Grant | A | 1.32 | 9,470 | 12,500 | 189,711 | 180.2 K to 189.7 K (+5.25 %) |
Nov 12 2014 | NAVB | NAVIDEA BIOPHARMAC ... | KARSEN PERRY A | Director | Grant | A | 1.32 | 10,252 | 13,533 | 30,252 | 20 K to 30.3 K (+51.26 %) |
Nov 12 2014 | NAVB | NAVIDEA BIOPHARMAC ... | Rowinsky Eric K | Director | Grant | A | 1.32 | 9,470 | 12,500 | 163,720 | 154.3 K to 163.7 K (+6.14 %) |
Nov 12 2014 | NAVB | NAVIDEA BIOPHARMAC ... | Troup Gordon A | Director | Grant | A | 1.32 | 16,099 | 21,251 | 182,349 | 166.3 K to 182.3 K (+9.68 %) |
Oct 08 2014 | NAVB | NAVIDEA BIOPHARMAC ... | Tulip Thomas H. | President | Payment of Exercise | F | 1.34 | 6,582 | 8,820 | 58,418 | 65 K to 58.4 K (-10.13 %) |
Oct 08 2014 | NAVB | NAVIDEA BIOPHARMAC ... | Tulip Thomas H. | President | Grant | A | 0.00 | 20,000 | 0 | 65,000 | 45 K to 65 K (+44.44 %) |
Sep 04 2014 | NAVB | NAVIDEA BIOPHARMAC ... | Nordlicht Mark | 10% Owner | Sell | S | 1.36 | 60,000 | 81,552 | 14,946,431 | 15 M to 14.9 M (-0.40 %) |
Jun 03 2014 | NAVB | NAVIDEA BIOPHARMAC ... | PYKETT MARK JEROME | Director | Grant | A | 0.00 | 20,000 | 0 | 312,674 | 292.7 K to 312.7 K (+6.83 %) |
May 15 2014 | NAVB | NAVIDEA BIOPHARMAC ... | Regan William J. | SVP-Global Reg Affa ... | Buy | P | 1.43 | 100 | 143 | 10,000 | 9.9 K to 10 K (+1.01 %) |
May 15 2014 | NAVB | NAVIDEA BIOPHARMAC ... | Regan William J. | SVP-Global Reg Affa ... | Buy | P | 1.43 | 500 | 713 | 9,900 | 9.4 K to 9.9 K (+5.32 %) |
May 15 2014 | NAVB | NAVIDEA BIOPHARMAC ... | Regan William J. | SVP-Global Reg Affa ... | Buy | P | 1.43 | 4,400 | 6,283 | 9,400 | 5 K to 9.4 K (+88.00 %) |
May 13 2014 | NAVB | NAVIDEA BIOPHARMAC ... | PYKETT MARK JEROME | CEO | Buy | P | 1.34 | 10,000 | 13,400 | 292,674 | 282.7 K to 292.7 K (+3.54 %) |
Mar 11 2014 | NAVB | NAVIDEA BIOPHARMAC ... | PYKETT MARK JEROME | CEO | Sell | S | 1.96 | 120,000 | 235,200 | 282,674 | 402.7 K to 282.7 K (-29.80 %) |
Mar 11 2014 | NAVB | NAVIDEA BIOPHARMAC ... | LARSON BRENT L | EVP, CFO, Treas & S ... | Option Exercise | M | 0.49 | 50,000 | 24,500 | 0 | |
Mar 11 2014 | NAVB | NAVIDEA BIOPHARMAC ... | LARSON BRENT L | EVP, CFO, Treas & S ... | Sell | S | 1.96 | 41,500 | 81,340 | 319,184 | 360.7 K to 319.2 K (-11.51 %) |
Mar 11 2014 | NAVB | NAVIDEA BIOPHARMAC ... | LARSON BRENT L | EVP, CFO, Treas & S ... | Payment of Exercise | F | 1.99 | 12,312 | 24,501 | 360,684 | 373 K to 360.7 K (-3.30 %) |
Mar 11 2014 | NAVB | NAVIDEA BIOPHARMAC ... | LARSON BRENT L | EVP, CFO, Treas & S ... | Buy | M | 0.49 | 50,000 | 24,500 | 372,996 | 323 K to 373 K (+15.48 %) |
Mar 11 2014 | NAVB | NAVIDEA BIOPHARMAC ... | Cope Frederick O | SVP | Sell | S | 1.96 | 15,000 | 29,400 | 75,814 | 90.8 K to 75.8 K (-16.52 %) |
Feb 19 2014 | NAVB | NAVIDEA BIOPHARMAC ... | KARSEN PERRY A | Director | Grant | A | 0.00 | 20,000 | 0 | 20,000 | 0 to 20 K |
Feb 18 2014 | NAVB | NAVIDEA BIOPHARMAC ... | Troup Gordon A | Director | Grant | A | 0.00 | 20,000 | 0 | 166,250 | 146.3 K to 166.3 K (+13.68 %) |
Feb 18 2014 | NAVB | NAVIDEA BIOPHARMAC ... | Rowinsky Eric K | Director | Grant | A | 0.00 | 20,000 | 0 | 154,250 | 134.3 K to 154.3 K (+14.90 %) |
Feb 18 2014 | NAVB | NAVIDEA BIOPHARMAC ... | GOLDBERG MICHAEL M | Director | Grant | A | 0.00 | 20,000 | 0 | 180,241 | 160.2 K to 180.2 K (+12.48 %) |
Feb 18 2014 | NAVB | NAVIDEA BIOPHARMAC ... | FORD BRENDAN A | Director | Grant | A | 0.00 | 20,000 | 0 | 159,250 | 139.3 K to 159.3 K (+14.36 %) |
Feb 18 2014 | NAVB | NAVIDEA BIOPHARMAC ... | DRAKE PETER F | Director | Grant | A | 0.00 | 20,000 | 0 | 59,250 | 39.3 K to 59.3 K (+50.96 %) |
Feb 18 2014 | NAVB | NAVIDEA BIOPHARMAC ... | DRAKE PETER F | Director | Grant | A | 0.00 | 20,000 | 0 | 59,250 | 39.3 K to 59.3 K (+50.96 %) |
Jan 31 2014 | NAVB | NAVIDEA BIOPHARMAC ... | Reininger Cornelia | SVP & Chief Medical ... | Option Exercise | A | 1.77 | 143,000 | 253,110 | 143,000 | |
Jan 31 2014 | NAVB | NAVIDEA BIOPHARMAC ... | Regan William J. | SVP-Global Regulato ... | Option Exercise | A | 1.77 | 85,000 | 150,450 | 85,000 | |
Jan 31 2014 | NAVB | NAVIDEA BIOPHARMAC ... | Cope Frederick O | SVP | Option Exercise | A | 1.77 | 133,000 | 235,410 | 133,000 | |
Jan 31 2014 | NAVB | NAVIDEA BIOPHARMAC ... | LARSON BRENT L | EVP, CFO, Treas & S ... | Option Exercise | A | 1.77 | 124,000 | 219,480 | 124,000 | |
Jan 31 2014 | NAVB | NAVIDEA BIOPHARMAC ... | Tulip Thomas H. | Option Exercise | A | 1.77 | 150,000 | 265,500 | 150,000 | ||
Jan 31 2014 | NAVB | NAVIDEA BIOPHARMAC ... | PYKETT MARK JEROME | CEO | Option Exercise | A | 1.77 | 258,000 | 456,660 | 258,000 | |
Jan 09 2014 | NAVB | NAVIDEA BIOPHARMAC ... | LARSON BRENT L | EVP, CFO, Treas & S ... | Option Exercise | M | 0.30 | 70,000 | 21,000 | 0 | |
Jan 09 2014 | NAVB | NAVIDEA BIOPHARMAC ... | LARSON BRENT L | EVP, CFO, Treas & S ... | Payment of Exercise | F | 1.93 | 34,308 | 66,214 | 322,996 | 357.3 K to 323 K (-9.60 %) |
Jan 09 2014 | NAVB | NAVIDEA BIOPHARMAC ... | LARSON BRENT L | EVP, CFO, Treas & S ... | Buy | M | 0.30 | 70,000 | 21,000 | 357,304 | 287.3 K to 357.3 K (+24.36 %) |
Nov 08 2013 | NAVB | NAVIDEA BIOPHARMAC ... | Cope Frederick O | SVP | Buy | P | 1.43 | 3,500 | 5,005 | 90,814 | 87.3 K to 90.8 K (+4.01 %) |
Nov 20 2013 | NAVB | NAVIDEA BIOPHARMAC ... | GOLDBERG MICHAEL M | Director | Grant | A | 0.00 | 12,250 | 0 | 160,241 | 148 K to 160.2 K (+8.28 %) |
Nov 08 2013 | NAVB | NAVIDEA BIOPHARMAC ... | Troup Gordon A | Director | Buy | P | 1.36 | 20,000 | 27,158 | 146,250 | 126.3 K to 146.3 K (+15.84 %) |
Nov 08 2013 | NAVB | NAVIDEA BIOPHARMAC ... | PYKETT MARK JEROME | CEO | Buy | P | 1.35 | 10,900 | 14,715 | 402,674 | 391.8 K to 402.7 K (+2.78 %) |
Nov 08 2013 | NAVB | NAVIDEA BIOPHARMAC ... | FORD BRENDAN A | Director | Buy | P | 1.45 | 20,000 | 29,000 | 139,250 | 119.3 K to 139.3 K (+16.77 %) |
Nov 08 2013 | NAVB | NAVIDEA BIOPHARMAC ... | LARSON BRENT L | EVP, CFO, Treas & S ... | Buy | P | 1.39 | 5,000 | 6,950 | 287,304 | 282.3 K to 287.3 K (+1.77 %) |
Mar 18 2013 | NAVB | NAVIDEA BIOPHARMAC ... | Troup Gordon A | Director | Buy | P | 2.70 | 7,000 | 18,893 | 126,250 | 119.3 K to 126.3 K (+5.87 %) |
Mar 18 2013 | NAVB | NAVIDEA BIOPHARMAC ... | PYKETT MARK JEROME | Pres. & CEO | Buy | P | 2.70 | 1,850 | 4,995 | 355,914 | 354.1 K to 355.9 K (+0.52 %) |
Mar 18 2013 | NAVB | NAVIDEA BIOPHARMAC ... | FORD BRENDAN A | Director | Buy | P | 2.71 | 5,000 | 13,550 | 119,250 | 114.3 K to 119.3 K (+4.38 %) |
Mar 18 2013 | NAVB | NAVIDEA BIOPHARMAC ... | Regan William J. | SVP-Global Regulato ... | Buy | P | 2.71 | 5,000 | 13,550 | 5,000 | 0 to 5 K |
Mar 18 2013 | NAVB | NAVIDEA BIOPHARMAC ... | Tulip Thomas H. | EVP & Chief Busines ... | Buy | P | 2.82 | 17,500 | 49,350 | 45,000 | 27.5 K to 45 K (+63.64 %) |
Mar 15 2013 | NAVB | NAVIDEA BIOPHARMAC ... | PYKETT MARK JEROME | Pres. & CEO | Payment of Exercise | F | 3.16 | 43,236 | 136,626 | 354,064 | 397.3 K to 354.1 K (-10.88 %) |
Mar 15 2013 | NAVB | NAVIDEA BIOPHARMAC ... | PYKETT MARK JEROME | Pres. & CEO | Grant | A | 0.00 | 125,000 | 0 | 397,300 | 272.3 K to 397.3 K (+45.91 %) |
Mar 15 2013 | NAVB | NAVIDEA BIOPHARMAC ... | Rowinsky Eric K | Director | Grant | A | 0.00 | 30,000 | 0 | 134,250 | 104.3 K to 134.3 K (+28.78 %) |
Mar 15 2013 | NAVB | NAVIDEA BIOPHARMAC ... | FORD BRENDAN A | Director | Grant | A | 0.00 | 30,000 | 0 | 114,250 | 84.3 K to 114.3 K (+35.61 %) |
Mar 15 2013 | NAVB | NAVIDEA BIOPHARMAC ... | Troup Gordon A | Director | Grant | A | 0.00 | 30,000 | 0 | 119,250 | 89.3 K to 119.3 K (+33.61 %) |
Mar 15 2013 | NAVB | NAVIDEA BIOPHARMAC ... | LARSON BRENT L | SVP, CFO, Treas & S ... | Payment of Exercise | F | 3.16 | 42,821 | 135,314 | 282,304 | 325.1 K to 282.3 K (-13.17 %) |
Mar 15 2013 | NAVB | NAVIDEA BIOPHARMAC ... | LARSON BRENT L | SVP, CFO, Treas & S ... | Grant | A | 0.00 | 125,000 | 0 | 325,125 | 200.1 K to 325.1 K (+62.46 %) |
Mar 15 2013 | NAVB | NAVIDEA BIOPHARMAC ... | Cope Frederick O | SVP | Payment of Exercise | F | 3.16 | 42,686 | 134,888 | 87,314 | 130 K to 87.3 K (-32.84 %) |
Mar 15 2013 | NAVB | NAVIDEA BIOPHARMAC ... | Cope Frederick O | SVP | Grant | A | 0.00 | 125,000 | 0 | 130,000 | 5 K to 130 K (+2,500.00 %) |
Mar 15 2013 | NAVB | NAVIDEA BIOPHARMAC ... | BROWN RODGER A | Vice President | Payment of Exercise | F | 3.16 | 16,194 | 51,173 | 123,027 | 139.2 K to 123 K (-11.63 %) |
Mar 15 2013 | NAVB | NAVIDEA BIOPHARMAC ... | BROWN RODGER A | Vice President | Grant | A | 0.00 | 45,000 | 0 | 139,221 | 94.2 K to 139.2 K (+47.76 %) |
Feb 26 2013 | NAVB | NAVIDEA BIOPHARMAC ... | Troup Gordon A | Director | Grant | A | 0.00 | 12,250 | 0 | 89,250 | 77 K to 89.3 K (+15.91 %) |
Feb 26 2013 | NAVB | NAVIDEA BIOPHARMAC ... | Rowinsky Eric K | Director | Grant | A | 0.00 | 12,250 | 0 | 104,250 | 92 K to 104.3 K (+13.32 %) |
Feb 26 2013 | NAVB | NAVIDEA BIOPHARMAC ... | JONES JESS | Director | Grant | A | 0.00 | 12,250 | 0 | 29,250 | 17 K to 29.3 K (+72.06 %) |
Feb 26 2013 | NAVB | NAVIDEA BIOPHARMAC ... | FORD BRENDAN A | Director | Grant | A | 0.00 | 12,250 | 0 | 84,250 | 72 K to 84.3 K (+17.01 %) |
Feb 26 2013 | NAVB | NAVIDEA BIOPHARMAC ... | DRAKE PETER F | Director | Grant | A | 0.00 | 12,250 | 0 | 39,250 | 27 K to 39.3 K (+45.37 %) |
Feb 19 2013 | NAVB | NAVIDEA BIOPHARMAC ... | Cope Frederick O | SVP | Option Exercise | A | 3.08 | 145,000 | 446,600 | 145,000 | |
Feb 19 2013 | NAVB | NAVIDEA BIOPHARMAC ... | Tulip Thomas H. | Option Exercise | A | 3.08 | 174,000 | 535,920 | 174,000 | ||
Feb 19 2013 | NAVB | NAVIDEA BIOPHARMAC ... | Reininger Cornelia | SVP & Chief Medical ... | Option Exercise | A | 3.08 | 120,000 | 369,600 | 120,000 | |
Feb 19 2013 | NAVB | NAVIDEA BIOPHARMAC ... | Regan William J. | SVP-Global Regulato ... | Option Exercise | A | 3.08 | 100,000 | 308,000 | 100,000 | |
Feb 19 2013 | NAVB | NAVIDEA BIOPHARMAC ... | LARSON BRENT L | SVP, CFO, Treas & S ... | Option Exercise | A | 3.08 | 142,000 | 437,360 | 142,000 | |
Feb 19 2013 | NAVB | NAVIDEA BIOPHARMAC ... | PYKETT MARK JEROME | Pres. & CEO | Option Exercise | A | 3.08 | 304,000 | 936,320 | 304,000 | |
Feb 19 2013 | NAVB | NAVIDEA BIOPHARMAC ... | PYKETT MARK JEROME | Pres. & CEO | Sell | D | 3.08 | 35,000 | 107,800 | 272,300 | 307.3 K to 272.3 K (-11.39 %) |
Nov 29 2012 | NAVB | NAVIDEA BIOPHARMAC ... | Platinum-Montaur Life Sciences ... | 10% Owner | Sell | J | 2.58 | 3,001,860 | 7,744,799 | 3,799,156 | 6.8 M to 3.8 M (-44.14 %) |
Nov 09 2012 | NAVB | NAVIDEA BIOPHARMAC ... | Platinum-Montaur Life Sciences ... | 10% Owner | Buy | P | 2.56 | 37,030 | 94,797 | 6,801,016 | 6.8 M to 6.8 M (+0.55 %) |
Nov 09 2012 | NAVB | NAVIDEA BIOPHARMAC ... | Platinum-Montaur Life Sciences ... | 10% Owner | Sell | S | 3.24 | 4,911 | 15,912 | 6,763,986 | 6.8 M to 6.8 M (-0.07 %) |
Nov 09 2012 | NAVB | NAVIDEA BIOPHARMAC ... | Platinum-Montaur Life Sciences ... | 10% Owner | Sell | S | 3.22 | 21,700 | 69,874 | 6,768,897 | 6.8 M to 6.8 M (-0.32 %) |
Nov 09 2012 | NAVB | NAVIDEA BIOPHARMAC ... | Platinum-Montaur Life Sciences ... | 10% Owner | Sell | S | 3.69 | 269,919 | 996,001 | 6,790,597 | 7.1 M to 6.8 M (-3.82 %) |
Nov 09 2012 | NAVB | NAVIDEA BIOPHARMAC ... | Platinum-Montaur Life Sciences ... | 10% Owner | Sell | S | 3.75 | 20,500 | 76,875 | 7,060,516 | 7.1 M to 7.1 M (-0.29 %) |
Nov 09 2012 | NAVB | NAVIDEA BIOPHARMAC ... | Platinum-Montaur Life Sciences ... | 10% Owner | Sell | S | 3.61 | 118,731 | 428,619 | 7,081,016 | 7.2 M to 7.1 M (-1.65 %) |
Nov 09 2012 | NAVB | NAVIDEA BIOPHARMAC ... | Platinum-Montaur Life Sciences ... | 10% Owner | Sell | S | 3.71 | 2,200 | 8,162 | 7,199,747 | 7.2 M to 7.2 M (-0.03 %) |
Nov 09 2012 | NAVB | NAVIDEA BIOPHARMAC ... | Platinum-Montaur Life Sciences ... | 10% Owner | Sell | S | 3.78 | 64,900 | 245,322 | 7,201,947 | 7.3 M to 7.2 M (-0.89 %) |
Nov 09 2012 | NAVB | NAVIDEA BIOPHARMAC ... | Platinum-Montaur Life Sciences ... | 10% Owner | Sell | S | 3.80 | 205,521 | 780,980 | 7,266,847 | 7.5 M to 7.3 M (-2.75 %) |
Nov 02 2012 | NAVB | NAVIDEA BIOPHARMAC ... | Reininger Cornelia | SVP & Chief Medical ... | Option Exercise | A | 2.85 | 88,000 | 250,800 | 88,000 | |
Sep 27 2012 | NAVB | NAVIDEA BIOPHARMAC ... | Rowinsky Eric K | Director | Grant | A | 0.00 | 30,000 | 0 | 92,000 | 62 K to 92 K (+48.39 %) |
Sep 14 2012 | NAVB | NAVIDEA BIOPHARMAC ... | Tulip Thomas H. | Buy | P | 2.70 | 15,000 | 40,500 | 27,500 | 12.5 K to 27.5 K (+120.00 %) | |
Sep 14 2012 | NAVB | NAVIDEA BIOPHARMAC ... | PYKETT MARK JEROME | Pres. & CEO | Buy | P | 2.64 | 4,000 | 10,552 | 307,300 | 303.3 K to 307.3 K (+1.32 %) |
Sep 13 2012 | NAVB | NAVIDEA BIOPHARMAC ... | Troup Gordon A | Director | Buy | P | 2.64 | 5,000 | 13,185 | 77,000 | 72 K to 77 K (+6.94 %) |
Sep 13 2012 | NAVB | NAVIDEA BIOPHARMAC ... | Troup Gordon A | Director | Buy | P | 3.58 | 5,000 | 17,895 | 72,000 | 67 K to 72 K (+7.46 %) |
Sep 13 2012 | NAVB | NAVIDEA BIOPHARMAC ... | FORD BRENDAN A | Director | Buy | P | 2.64 | 5,000 | 13,200 | 72,000 | 67 K to 72 K (+7.46 %) |
Apr 23 2012 | NAVB | NAVIDEA BIOPHARMAC ... | Tulip Thomas H. | Sell | D | 2.69 | 7,500 | 20,175 | 12,500 | 20 K to 12.5 K (-37.50 %) | |
Apr 23 2012 | NAVB | NAVIDEA BIOPHARMAC ... | LARSON BRENT L | SVP, CFO, Treas & S ... | Sell | D | 2.69 | 15,000 | 40,350 | 200,125 | 215.1 K to 200.1 K (-6.97 %) |
Apr 23 2012 | NAVB | NAVIDEA BIOPHARMAC ... | BROWN RODGER A | Vice President | Sell | D | 2.69 | 15,000 | 40,350 | 94,221 | 109.2 K to 94.2 K (-13.73 %) |
Apr 11 2012 | NAVB | NAVIDEA BIOPHARMAC ... | JONES JESS | Director | Grant | A | 0.00 | 17,000 | 0 | 17,000 | 0 to 17 K |
Apr 11 2012 | NAVB | NAVIDEA BIOPHARMAC ... | Troup Gordon A | Director | Grant | A | 0.00 | 17,000 | 0 | 67,000 | 50 K to 67 K (+34.00 %) |
Apr 11 2012 | NAVB | NAVIDEA BIOPHARMAC ... | Rowinsky Eric K | Director | Grant | A | 0.00 | 17,000 | 0 | 62,000 | 45 K to 62 K (+37.78 %) |
Apr 11 2012 | NAVB | NAVIDEA BIOPHARMAC ... | FORD BRENDAN A | Director | Grant | A | 0.00 | 17,000 | 0 | 67,000 | 50 K to 67 K (+34.00 %) |
Apr 11 2012 | NAVB | NAVIDEA BIOPHARMAC ... | DRAKE PETER F | Director | Grant | A | 0.00 | 17,000 | 0 | 27,000 | 10 K to 27 K (+170.00 %) |
Feb 22 2012 | NAVB | NAVIDEA BIOPHARMAC ... | Rowinsky Eric K | Director | Grant | A | 0.00 | 30,000 | 0 | 45,000 | 15 K to 45 K (+200.00 %) |
Feb 22 2012 | NAVB | NAVIDEA BIOPHARMAC ... | LARSON BRENT L | SVP, CFO, Treas & S ... | Option Exercise | A | 3.28 | 88,000 | 288,640 | 88,000 | |
Feb 22 2012 | NAVB | NAVIDEA BIOPHARMAC ... | BROWN RODGER A | Vice President | Option Exercise | A | 3.28 | 65,000 | 213,200 | 65,000 | |
Feb 22 2012 | NAVB | NAVIDEA BIOPHARMAC ... | Cope Frederick O | SVP | Option Exercise | A | 3.28 | 127,000 | 416,560 | 127,000 | |
Feb 22 2012 | NAVB | NAVIDEA BIOPHARMAC ... | Tulip Thomas H. | Option Exercise | A | 3.28 | 163,000 | 534,640 | 163,000 | ||
Feb 22 2012 | NAVB | NAVIDEA BIOPHARMAC ... | Tulip Thomas H. | Grant | A | 0.00 | 20,000 | 0 | 20,000 | 0 to 20 K | |
Feb 22 2012 | NAVB | NAVIDEA BIOPHARMAC ... | PYKETT MARK JEROME | Pres. & CEO | Option Exercise | A | 3.28 | 250,000 | 820,000 | 250,000 | |
Feb 22 2012 | NAVB | NAVIDEA BIOPHARMAC ... | PYKETT MARK JEROME | Pres. & CEO | Grant | A | 0.00 | 300,000 | 0 | 303,300 | 3.3 K to 303.3 K (+9,090.91 %) |
Dec 20 2011 | NAVB | NAVIDEA BIOPHARMAC ... | BUPP DAVID C | Director | Sell | S | 2.54 | 7,814 | 19,848 | 2,750,328 | 2.8 M to 2.8 M (-0.28 %) |
Dec 20 2011 | NAVB | NAVIDEA BIOPHARMAC ... | BUPP DAVID C | Director | Sell | S | 2.45 | 42,186 | 103,356 | 2,758,142 | 2.8 M to 2.8 M (-1.51 %) |
Dec 20 2011 | NAVB | NAVIDEA BIOPHARMAC ... | BUPP DAVID C | Director | Grant | A | 0.00 | 300,000 | 0 | 2,900,328 | 2.6 M to 2.9 M (+11.54 %) |
Nov 22 2011 | NAVB | NAVIDEA BIOPHARMAC ... | BUPP DAVID C | Director | Sell | S | 2.19 | 10,000 | 21,900 | 2,500,328 | 2.5 M to 2.5 M (-0.40 %) |
Nov 22 2011 | NAVB | NAVIDEA BIOPHARMAC ... | BUPP DAVID C | Director | Sell | S | 2.25 | 6,100 | 13,725 | 2,510,328 | 2.5 M to 2.5 M (-0.24 %) |
Nov 22 2011 | NAVB | NAVIDEA BIOPHARMAC ... | BUPP DAVID C | Director | Sell | S | 2.27 | 10,000 | 22,700 | 2,516,428 | 2.5 M to 2.5 M (-0.40 %) |
Nov 21 2011 | NAVB | NAVIDEA BIOPHARMAC ... | BUPP DAVID C | Director | Sell | S | 2.28 | 23,900 | 54,492 | 2,526,428 | 2.6 M to 2.5 M (-0.94 %) |
Nov 02 2011 | NAVB | NAVIDEA BIOPHARMAC ... | LARSON BRENT L | SVP, CFO, Treas & S ... | Option Exercise | M | 0.13 | 30,000 | 3,900 | 0 | |
Nov 02 2011 | NAVB | NAVIDEA BIOPHARMAC ... | LARSON BRENT L | SVP, CFO, Treas & S ... | Option Exercise | M | 0.14 | 40,000 | 5,600 | 0 | |
Nov 02 2011 | NAVB | NAVIDEA BIOPHARMAC ... | LARSON BRENT L | SVP, CFO, Treas & S ... | Option Exercise | M | 0.42 | 50,000 | 21,000 | 0 | |
Nov 02 2011 | NAVB | NAVIDEA BIOPHARMAC ... | LARSON BRENT L | SVP, CFO, Treas & S ... | Payment of Exercise | F | 2.84 | 41,824 | 118,780 | 220,588 | 262.4 K to 220.6 K (-15.94 %) |
Nov 02 2011 | NAVB | NAVIDEA BIOPHARMAC ... | LARSON BRENT L | SVP, CFO, Treas & S ... | Sell | S | 2.75 | 12,500 | 34,375 | 262,412 | 274.9 K to 262.4 K (-4.55 %) |
Nov 02 2011 | NAVB | NAVIDEA BIOPHARMAC ... | LARSON BRENT L | SVP, CFO, Treas & S ... | Buy | M | 0.13 | 30,000 | 3,900 | 274,912 | 244.9 K to 274.9 K (+12.25 %) |
Nov 02 2011 | NAVB | NAVIDEA BIOPHARMAC ... | LARSON BRENT L | SVP, CFO, Treas & S ... | Buy | M | 0.14 | 40,000 | 5,600 | 244,912 | 204.9 K to 244.9 K (+19.52 %) |
Nov 02 2011 | NAVB | NAVIDEA BIOPHARMAC ... | LARSON BRENT L | SVP, CFO, Treas & S ... | Buy | M | 0.42 | 50,000 | 21,000 | 204,912 | 154.9 K to 204.9 K (+32.28 %) |
Oct 18 2011 | NAVB | NAVIDEA BIOPHARMAC ... | DRAKE PETER F | Director | Buy | P | 3.08 | 10,000 | 30,780 | 10,000 | 0 to 10 K |
Nov 02 2011 | NAVB | NAVIDEA BIOPHARMAC ... | BROWN RODGER A | Vice President | Option Exercise | M | 0.13 | 30,000 | 3,900 | 0 | |
Nov 02 2011 | NAVB | NAVIDEA BIOPHARMAC ... | BROWN RODGER A | Vice President | Option Exercise | M | 0.14 | 40,000 | 5,600 | 0 | |
Nov 02 2011 | NAVB | NAVIDEA BIOPHARMAC ... | BROWN RODGER A | Vice President | Option Exercise | M | 0.30 | 70,000 | 21,000 | 0 | |
Nov 02 2011 | NAVB | NAVIDEA BIOPHARMAC ... | BROWN RODGER A | Vice President | Option Exercise | M | 0.42 | 50,000 | 21,000 | 0 | |
Nov 02 2011 | NAVB | NAVIDEA BIOPHARMAC ... | BROWN RODGER A | Vice President | Payment of Exercise | F | 2.84 | 67,029 | 190,362 | 122,971 | 190 K to 123 K (-35.28 %) |
Nov 02 2011 | NAVB | NAVIDEA BIOPHARMAC ... | BROWN RODGER A | Vice President | Sell | S | 2.76 | 28,715 | 79,253 | 190,000 | 218.7 K to 190 K (-13.13 %) |
Nov 02 2011 | NAVB | NAVIDEA BIOPHARMAC ... | BROWN RODGER A | Vice President | Buy | M | 0.13 | 30,000 | 3,900 | 218,715 | 188.7 K to 218.7 K (+15.90 %) |
Nov 02 2011 | NAVB | NAVIDEA BIOPHARMAC ... | BROWN RODGER A | Vice President | Buy | M | 0.14 | 40,000 | 5,600 | 188,715 | 148.7 K to 188.7 K (+26.90 %) |
Nov 02 2011 | NAVB | NAVIDEA BIOPHARMAC ... | BROWN RODGER A | Vice President | Buy | M | 0.42 | 50,000 | 21,000 | 148,715 | 98.7 K to 148.7 K (+50.65 %) |
Nov 02 2011 | NAVB | NAVIDEA BIOPHARMAC ... | BROWN RODGER A | Vice President | Buy | M | 0.30 | 70,000 | 21,000 | 98,715 | 28.7 K to 98.7 K (+243.78 %) |
Oct 19 2011 | NAVB | NAVIDEA BIOPHARMAC ... | BUPP DAVID C | Director | Sell | S | 2.89 | 50,000 | 144,500 | 2,550,328 | 2.6 M to 2.6 M (-1.92 %) |
Oct 19 2011 | NAVB | NAVIDEA BIOPHARMAC ... | BUPP DAVID C | Director | Gift | G | 0.00 | 13,000 | 0 | 2,600,328 | 2.6 M to 2.6 M (-0.50 %) |
Aug 23 2011 | NAVB | NAVIDEA BIOPHARMAC ... | FORD BRENDAN A | Director | Buy | P | 2.51 | 20,000 | 50,200 | 50,000 | 30 K to 50 K (+66.67 %) |
Aug 23 2011 | NAVB | NAVIDEA BIOPHARMAC ... | Rowinsky Eric K | Director | Buy | P | 2.55 | 15,000 | 38,250 | 15,000 | 0 to 15 K |
Aug 23 2011 | NAVB | NAVIDEA BIOPHARMAC ... | PYKETT MARK JEROME | Pres. & CEO | Buy | P | 2.56 | 1,100 | 2,816 | 1,100 | 0 to 1.1 K |
Aug 23 2011 | NAVB | NAVIDEA BIOPHARMAC ... | PYKETT MARK JEROME | Pres. & CEO | Buy | P | 2.56 | 100 | 256 | 3,300 | 3.2 K to 3.3 K (+3.13 %) |
Aug 23 2011 | NAVB | NAVIDEA BIOPHARMAC ... | PYKETT MARK JEROME | Pres. & CEO | Buy | P | 2.60 | 500 | 1,300 | 3,200 | 2.7 K to 3.2 K (+18.52 %) |
Aug 23 2011 | NAVB | NAVIDEA BIOPHARMAC ... | PYKETT MARK JEROME | Pres. & CEO | Buy | P | 2.61 | 2,700 | 7,047 | 2,700 | 0 to 2.7 K |
Aug 23 2011 | NAVB | NAVIDEA BIOPHARMAC ... | Troup Gordon A | Director | Buy | P | 2.61 | 10,000 | 26,100 | 50,000 | 40 K to 50 K (+25.00 %) |
Aug 19 2011 | NAVB | NAVIDEA BIOPHARMAC ... | Tulip Thomas H. | Option Exercise | A | 4.93 | 110,000 | 542,300 | 110,000 | ||
Aug 05 2011 | NAVB | NAVIDEA BIOPHARMAC ... | Rowinsky Eric K | Director | Option Exercise | A | 2.56 | 60,000 | 153,600 | 60,000 | |
Jun 07 2011 | NAVB | NAVIDEA BIOPHARMAC ... | BUPP DAVID C | Director | Sell | S | 4.52 | 234,000 | 1,057,680 | 2,613,328 | 2.8 M to 2.6 M (-8.22 %) |
Jun 07 2011 | NAVB | NAVIDEA BIOPHARMAC ... | BUPP DAVID C | Director | Grant | A | 0.00 | 300,000 | 0 | 2,543,328 | 2.2 M to 2.5 M (+13.37 %) |
Jun 03 2011 | NAVB | NAVIDEA BIOPHARMAC ... | BUPP DAVID C | Director | Sell | S | 4.74 | 233,000 | 1,104,420 | 2,547,328 | 2.8 M to 2.5 M (-8.38 %) |
Jun 03 2011 | NAVB | NAVIDEA BIOPHARMAC ... | BUPP DAVID C | Director | Sell | S | 5.00 | 233,000 | 1,165,000 | 2,780,328 | 3 M to 2.8 M (-7.73 %) |
Jun 01 2011 | NAVB | NAVIDEA BIOPHARMAC ... | Blair Anthony K | VP-Manufacturing & ... | Sell | S | 5.22 | 50,000 | 261,000 | 0 | 50 K to 0 (-100.00 %) |
May 31 2011 | NAVB | NAVIDEA BIOPHARMAC ... | BUPP DAVID C | Director | Option Exercise | X | 0.31 | 20,000 | 6,200 | 0 | |
May 31 2011 | NAVB | NAVIDEA BIOPHARMAC ... | BUPP DAVID C | Director | Option Exercise | X | 0.32 | 450,000 | 144,000 | 0 | |
May 31 2011 | NAVB | NAVIDEA BIOPHARMAC ... | BUPP DAVID C | Director | Option Exercise | X | 0.31 | 320,000 | 99,200 | 0 |